RhumbLine Advisers’s CASI Pharmaceuticals CASI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-7,159
| Closed | -$172K | – | 3004 |
|
|
2021
Q1 | $172K | Sell |
7,159
-170
| -2% | -$4.08K | ﹤0.01% | 2863 |
|
|
2020
Q4 | $216K | Buy |
7,329
+754
| +11% | +$22.2K | ﹤0.01% | 2807 |
|
|
2020
Q3 | $101K | Sell |
6,575
-828
| -11% | -$12.7K | ﹤0.01% | 2869 |
|
|
2020
Q2 | $185K | Buy |
7,403
+847
| +13% | +$21.2K | ﹤0.01% | 2798 |
|
|
2020
Q1 | $134K | Hold |
6,556
| – | – | ﹤0.01% | 2709 |
|
|
2019
Q4 | $203K | Buy |
6,556
+17
| +0.3% | +$526 | ﹤0.01% | 2742 |
|
|
2019
Q3 | $218K | Buy |
6,539
+26
| +0.4% | +$867 | ﹤0.01% | 2719 |
|
|
2019
Q2 | $208K | Buy |
6,513
+138
| +2% | +$4.41K | ﹤0.01% | 2774 |
|
|
2019
Q1 | $183K | Sell |
6,375
-65
| -1% | -$1.87K | ﹤0.01% | 2768 |
|
|
2018
Q4 | $259K | Buy |
6,440
+2,157
| +50% | +$86.7K | ﹤0.01% | 2609 |
|
|
2018
Q3 | $200K | Sell |
4,283
-262
| -6% | -$12.2K | ﹤0.01% | 2729 |
|
|
2018
Q2 | $374K | Buy |
+4,545
| New | +$374K | ﹤0.01% | 2437 |
|